{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/alopecia-androgenetic-male/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field e2cb715c-b8bd-4a94-a9b6-64ad24c3c16b --><h2>Changes</h2><!-- end field e2cb715c-b8bd-4a94-a9b6-64ad24c3c16b -->","summary":null,"htmlStringContent":"<!-- begin item 83ce9555-e860-470c-83df-f8b2d98988e7 --><!-- begin field 711766d2-fcf0-4bfe-9e72-74d3f96927cd --><p><strong>July 2018</strong> — minor update. Anxiety has been added as an adverse effect for men taking finasteride. </p><p><strong>June 2017</strong> — minor update. Addition to adverse effects section for depression and suicidal thoughts in men taking finasteride. </p><p><strong>April 2017</strong>  — minor update. Information on availability of minoxidil foam on FP10 prescription corrected</p><p><strong>May to June 2016</strong>  — reviewed. A literature search was conducted in May 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made, although minor restructuring of the topic has been undertaken.</p><!-- end field 711766d2-fcf0-4bfe-9e72-74d3f96927cd --><!-- end item 83ce9555-e860-470c-83df-f8b2d98988e7 -->","topic":{"id":"5f58d6a9-7ba5-59ad-b7d6-e461768e2621","topicId":"c4dc3303-ee1d-42aa-8da5-078adb684e06","topicName":"Alopecia, androgenetic - male","slug":"alopecia-androgenetic-male","lastRevised":"Last revised in July 2018","chapters":[{"id":"e3fc5b8b-475e-5a1f-a596-104fbf00064f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c40b9d81-bd18-5ef2-8284-4c4e6005d65c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"bbc072f8-3fd9-5a1c-b94c-a0e4fd6edc2f","slug":"changes","fullItemName":"Changes"},{"id":"746928be-2acf-5ae9-9f81-02a942d56a15","slug":"update","fullItemName":"Update"}]},{"id":"3f6cf011-8136-5f24-8cce-31a439cce866","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5e802365-89ef-5f47-a758-6c880bb456ac","slug":"goals","fullItemName":"Goals"},{"id":"9ed869e3-e3ae-56e1-ae20-0a46d6e20fa2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"d90f156b-7429-5580-b4c3-e50d840d1c8a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c879d8ad-590c-56af-9685-9eb9a2e30d54","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9e4f37dc-4cc8-5e88-a803-5ca32ca17da9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5df134be-2105-5321-86a8-71ed6dca8ebb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8a3725c2-b01f-5dd8-a319-33387b40d0ee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"762358f6-f003-57e8-97ff-1c81299e9364","slug":"definition","fullItemName":"Definition"},{"id":"9ee0c90d-fd96-523f-8f6f-7a26ec56b9c7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"55784b07-7a42-5c0b-9ff3-e9c83216cb1e","slug":"complications","fullItemName":"Complications"},{"id":"7cde82a5-0086-5e04-a669-ec49787685f0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"33fac4d7-a95d-526c-936a-6983e3a12d95","slug":"causes","fullItemName":"Causes"},{"id":"84f86e20-aa91-5e2b-b0b6-bb3cfbf655d6","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"4b1bf49e-974e-517b-abd6-59b7ea701502","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"486adc7a-b20b-584e-b20c-1408c8f2dc42","slug":"diagnosis-assessment","fullItemName":"Diagnosis and assessment"},{"id":"afbd97db-7525-51a6-aafe-6e937f1cc3e1","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"4fa73515-d20e-5178-9d6b-eebf5ae2d527","slug":"investigations","fullItemName":"Investigations"}]},{"id":"622bcbbb-d3de-5b15-9b55-ddc4eff327ab","fullItemName":"Management","slug":"management","subChapters":[{"id":"18247780-bdd9-5da4-9d33-1bcf2a883881","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"37e93d68-3a6a-5889-a376-afa236d390aa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"baab0697-37a1-5edf-88ac-cfb6e2e5656b","slug":"topical-minoxidil-2percent-5percent","fullItemName":"Topical minoxidil 2% and 5%"},{"id":"c42ae7ac-8352-5cac-874c-69c24b99081b","slug":"finasteride","fullItemName":"Finasteride"}]},{"id":"b22c3dba-eb5b-5afa-8f70-43908da7e430","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"444a2a47-2816-5baa-928f-c2bc1b56af85","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1d1c173f-70b1-5d42-916a-a0bcb5c3557c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"531d7be1-4263-5fd6-a49b-a920a3aaca95","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dede1c7c-59ec-550c-be37-91849715881e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ddffa446-a263-56e2-a985-c07fa5d06760","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3b6f4b5d-c7dd-5142-a6e8-2741d9019ade","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b9ed9ca-1edc-5d61-938a-a6abc5daa77a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d860e13e-49f1-54f2-872f-2f3439f27003","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ed6193ee-4a22-5ba1-acc6-c968ead0c7be","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 3ff075c2-1c71-430b-a865-bdd505dc16eb --><h3>Previous changes</h3><!-- end field 3ff075c2-1c71-430b-a865-bdd505dc16eb -->","summary":null,"htmlStringContent":"<!-- begin item 5dc204ba-b123-4096-9238-e3a63071eec7 --><!-- begin field 0475bccc-2cb1-4fa6-815f-4f0ee058f723 --><div><strong>November 2010 to February 2011 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</div><!-- end field 0475bccc-2cb1-4fa6-815f-4f0ee058f723 --><!-- end item 5dc204ba-b123-4096-9238-e3a63071eec7 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}